News from synthetic biologics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 19, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 16, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 11, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 09, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics to Report Year End 2014 Financial Results

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 03, 2015, 06:57 ET
MM19465LOGO

Synthetic Biologics to Present at the 27th Annual ROTH Conference

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Mar 02, 2015, 06:57 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Feb 17, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week® 2015

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Feb 10, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Announces Positive Topline Results from Phase 1b Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Feb 03, 2015, 06:56 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics to Present at the 2015 BIO CEO & Investor Conference

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Jan 07, 2015, 06:58 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics to Present at the Biotech Showcase™ 2015 Conference

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Dec 30, 2014, 07:58 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces First Patient Dosed in Phase 1b Clinical Trial of SYN-004 for the Prevention of C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Dec 22, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Dec 02, 2014, 08:04 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Nov 24, 2014, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Nov 14, 2014, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Nov 06, 2014, 06:57 ET

Synthetic Biologics to Report Third Quarter 2014 Financial Results

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Oct 22, 2014, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel pathogen-specific therapies for serious infections and...

Oct 15, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel Syndrome (IBS) Clinical Advisory Board

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologics and drugs targeting specific...

Oct 10, 2014, 08:55 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Raise $20.7 Million in Registered Direct Offering

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel biologics and drugs targeting specific pathogens that cause...